This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blay, J.-Y. Articles by Philip, T. Search for Related Content PubMed PubMed Citation Articles by Blay, J.-Y. Articles by Philip, T.

Correlation between Clinical Response to Interleukin 2 Therapy and Sustained Production of Tumor Necrosis Factor¹

Bone Marrow Transplant Unit and Radiology Department, Centre Léon Bérard, 28 rue Lannec, 69373 Lyon Cedex 8, France [J-Y. B., M. C. F., S. N., V. C., P. K., T. P.]; Hôpital Edouard Herriot, Lyon, France [S. N., A. M.]; Institut Gustave Roussy, Villejuif, France [J-Y. B., S. C.]; and Eurocetus, Amsterdam, The Netherlands [C. R. F.]

Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis factor (TNF) in serum before initiation of therapy. On the fifth day of therapy, 24 patients had circulating TNF with immunoradiometric assay whereas 13 had detectable biological activity. Two days after the end of IL2 therapy, TNF concentration (immunoradiometric assay) decreased in most cases but was still detectable in 17 patients. Thirteen patients had still circulating TNF bioactivity. Although there was no significant difference between TNF levels observed on the fifth day of therapy in the responder and nonresponder groups, 48 h after the end of IL2 infusion, both the TNF concentration and the biological activity were significantly higher in the group of responder patients. This result suggests that the clinical response to IL2 therapy in patients with metastatic renal cell carcinoma is correlated to a sustained production of TNF after the end of IL2 infusion.

¹ This work has been supported by Grant 6243 from Association pour la Recherche sur le Cancer and a grant from the Ligue Nationale Contre le Cancer, Comité Départemental de la Savoie.

² To whom requests for reprints should be addressed.

Received 9/ 5/89. Revised 1/ 3/90.

This article has been cited by other articles:

				T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al. Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors J. Immunol., May 15, 2006; 176(10): 6302 - 6312. [Abstract] [Full Text] [PDF]

				C. Menetrier-Caux, M. C. Thomachot, L. Alberti, G. Montmain, and J. Y. Blay IL-4 Prevents the Blockade of Dendritic Cell Differentiation Induced by Tumor Cells Cancer Res., April 1, 2001; 61(7): 3096 - 3104. [Abstract] [Full Text]

				E. Di Carlo, G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani The intriguing role of polymorphonuclear neutrophils in antitumor reactions Blood, January 15, 2001; 97(2): 339 - 345. [Full Text] [PDF]

				R. A. Tio, J. Nieken, E. G.E. de Vries, C. Pfeiffer, M. J.L. de Jongste, E. Pieper, H. Moshage, P. C. Limburg, and N. H. Mulder Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction Eur J Heart Fail, June 1, 2000; 2(2): 167 - 173. [Abstract] [Full Text] [PDF]

				Z. M. N. QUEZADO, W. KARZAI, R. L. DANNER, B. D. FREEMAN, L. YAN, P. Q. EICHACKER, S. M. BANKS, J. PERREN COBB, R. E. CUNNION, M. J. N. QUEZADO, et al. Effects of L-NMMA and Fluid Loading on TNF-induced Cardiovascular Dysfunction in Dogs Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1397 - 1405. [Abstract] [Full Text]